NCT01002417 - MCS in the Treatment of Lower Urinary Tract Symptoms | Biotech Hunter

Enrollment

274

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions

Lower Urinary Tract SymptomsBenign Prostatic Hyperplasia

Interventions

DRUG

MCS-2 15 mg/day

One MCS-2 15 mg soft-gel capsule plus one matching placebo capsule, oral daily for 12 weeks.

DRUG

MCS-2 30 mg/day

Two MCS-2 soft-gel capsules, oral daily for 12 weeks.

DRUG

Placebo

Two matching placebo soft-gel capsules, oral daily for 12 weeks.

Trial Locations (1)

David Geffen School of Medicine at UCLA, Los Angeles